Stallion Platinum 30000 Capsules in blue — Class I drug recall D-0655-2020
Terminated recall by Motto International Corp, reported 2020-01-22, distributed in TX. Marketed without an Approved NDA/ANDA; FDA analysis found product to contain tadalfil
| Recall number | D-0655-2020 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Motto International Corp, Dallas, TX, United States |
| Recall initiated | 2019-12-17 |
| Classified | 2020-01-10 |
| Reported by FDA | 2020-01-22 |
| Terminated | 2021-10-29 |
| Distributed | TX |
| Quantity | 7 boxes |
| Reason classes | unapproved product |
Product
Stallion Platinum 30000 Capsules in blue,orange,white background with red,white text in hologram paper packaging, packaged in 2, 4, 10 count blister cards, Motto International, Dallas, TX
Reason for recall
Marketed without an Approved NDA/ANDA; FDA analysis found product to contain tadalfil
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0655-2020. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.